S100A9 and hepatocellular carcinoma: Downregulation of DCLK1 inhibits HCV replication, hepatoma cell migration, tumor growth in an HCC xenograft model, EMT, and expression of myeloid-derived S100A9 protein, which suppresses anti-tumor immunity11,16–18,20–24.